Division of Signaling in Cancer and Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12425-30. doi: 10.1073/pnas.1106645108. Epub 2011 Jul 11.
Recent evidence has unveiled the critical role of tumor cells with stem cell activities in tumorigenicity and drug resistance, but how tumor microenvironments regulate cancer stem/initiating cells (CSCs) remains unknown. We clarified the role of tumor-associated macrophages (TAMs) and their downstream factor milk-fat globule-epidermal growth factor-VIII (MFG-E8) in the regulation of CSC activities. Bone marrow chimeric systems and adoptive cell transfers elucidated the importance of MFG-E8 from TAMs in conferring to CSCs with the ability to promote tumorigenicity and anticancer drug resistance. MFG-E8 mainly activates signal transducer and activator of transcription-3 (Stat3) and Sonic Hedgehog pathways in CSCs and further amplifies their anticancer drug resistance in cooperation with IL-6. Thus, the pharmacological targeting of key factors derived from tumor-associated inflammation provides a unique strategy to eradicate therapy-resistant tumors by manipulating CSC activities.
最近的证据揭示了具有干细胞活性的肿瘤细胞在肿瘤发生和耐药性中的关键作用,但肿瘤微环境如何调节癌症干细胞/起始细胞(CSCs)尚不清楚。我们阐明了肿瘤相关巨噬细胞(TAMs)及其下游因子乳脂肪球-表皮生长因子-VIII(MFG-E8)在调节 CSC 活性中的作用。骨髓嵌合系统和过继细胞转移阐明了 TAMs 中的 MFG-E8 对于赋予具有促进肿瘤发生和抗癌药物耐药性能力的 CSCs 的重要性。MFG-E8 主要在 CSCs 中激活信号转导子和转录激活子 3(Stat3)和 Sonic Hedgehog 途径,并与 IL-6 一起进一步放大它们的抗癌药物耐药性。因此,靶向源自肿瘤相关炎症的关键因子为通过操纵 CSC 活性来根除治疗耐药性肿瘤提供了一种独特的策略。